Theodoros Christophides*, Alberto Somaschini*, Andrea Demarchi, Stefano Cornara, Maria Androulaki and Emmanuel Androulakis Pages 1396 - 1406 ( 11 )
Essential hypertension is an important cause of cardiovascular morbidity and mortality worldwide with significant clinical and economic implications. The field of antihypertensive treatment already numbers numerous agents and classes of drugs. However, patients are still developing uncontrolled hypertension. Hence there is a continuous need for novel agents with good tolerability. Advances in this field are focusing both on pharmacotherapy, with the developments in traditional and non-traditional targets, as well as interventional techniques such as renal denervation and baroreflex activation therapy. It is likely that future strategies may involve a tailored approach to the individual patient, with genetic modulation playing a key role.
Hypertension, therapy, drug, intervention, novel, blood pressure.
Cardiology Department, Nicosia General Hospital, Nicosia, Royal Brompton & Harefield NHS Foundation Trust, London, Cardiocentro Ticino, Lugano, Department of Cardiology, San Paolo Hospital, Savona, General Hospital of Ierapetra, Crete, Royal Brompton & Harefield NHS Foundation Trust, London